ERS Genomics licenses gene editing tech to FASMAC

By The Science Advisory Board staff writers

October 14, 2020 -- ERS Genomics, which has access to foundational CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, has signed an agreement with FASMAC of Japan.

Under the terms of the nonexclusive agreement, FASMAC acquires the rights to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

FASMAC was established in 2001 to provide food analysis and biotechnology products and services, including DNA and RNA synthesis products, DNA sequencing services, food testing services, and genetic analysis reagents and kits.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.